Literature DB >> 9756780

Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.

A H Groll1, T Sein, V Petraitis, R Petraitiene, D Callender, C E Gonzalez, N Giri, J Bacher, S Piscitelli, T J Walsh.   

Abstract

The pharmacokinetics of the antifungal pradimicin derivative BMS 181184 in plasma of normal, catheterized rabbits were characterized after single and multiple daily intravenous administrations of dosages of 10, 25, 50, or 150 mg/kg of body weight, and drug levels in tissues were assessed after multiple dosing. Concentrations of BMS 181184 were determined by a validated high-performance liquid chromatography method, and plasma data were modeled into a two-compartment open model. Across the investigated dosage range, BMS 181184 demonstrated nonlinear, dose-dependent kinetics with enhanced clearance, reciprocal shortening of elimination half-life, and an apparently expanding volume of distribution with increasing dosage. After single-dose administration, the mean peak plasma BMS 181184 concentration (Cmax) ranged from 120 microg/ml at 10 mg/kg to 648 microg/ml at 150 mg/kg; the area under the concentration-time curve from 0 to 24 h (AUC0-24) ranged from 726 to 2,130 microg . h/ml, the volume of distribution ranged from 0.397 to 0.799 liter/kg, and the terminal half-life ranged from 4.99 to 2.31 h, respectively (P < 0.005 to P < 0.001). No drug accumulation in plasma occurred after multiple daily dosing at 10, 25, or 50 mg/kg over 15 days, although mean elimination half-lives were slightly longer. Multiple daily dosing at 150 mg/kg was associated with enhanced total clearance and a significant decrease in AUC0-24 below the values obtained at 50 mg/kg (P < 0.01) and after single-dose administration of the same dosage (P < 0.05). Assessment of tissue BMS 181184 concentrations after multiple dosing over 16 days revealed substantial uptake in the lungs, liver, and spleen and, most notably, dose-dependent accumulation of the drug within the kidneys. These findings are indicative of dose- and time-dependent elimination of BMS 181184 from plasma and renal accumulation of the compound after multiple dosing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756780      PMCID: PMC105922     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro and in vivo antifungal activities of BMS-181184.

Authors:  T Oki; M Kakushima; M Hirano; A Takahashi; A Ohta; S Masuyoshi; M Hatori; H Kamei
Journal:  J Antibiot (Tokyo)       Date:  1992-09       Impact factor: 2.649

2.  Calcium-dependent anticandidal action of pradimicin A.

Authors:  Y Sawada; K Numata; T Murakami; H Tanimichi; S Yamamoto; T Oki
Journal:  J Antibiot (Tokyo)       Date:  1990-06       Impact factor: 2.649

3.  Pradimicin, a novel class of potent antifungal antibiotics.

Authors:  T Oki; M Konishi; K Tomatsu; K Tomita; K Saitoh; M Tsunakawa; M Nishio; T Miyaki; H Kawaguchi
Journal:  J Antibiot (Tokyo)       Date:  1988-11       Impact factor: 2.649

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities.

Authors:  T Oki; O Tenmyo; M Hirano; K Tomatsu; H Kamei
Journal:  J Antibiot (Tokyo)       Date:  1990-07       Impact factor: 2.649

6.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

7.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

Authors:  A H Groll; P M Shah; C Mentzel; M Schneider; G Just-Nuebling; K Huebner
Journal:  J Infect       Date:  1996-07       Impact factor: 6.072

8.  In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative.

Authors:  M Kakushima; S Masuyoshi; M Hirano; M Shinoda; A Ohta; H Kamei; T Oki
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Authors:  J C Fung-Tomc; B Minassian; E Huczko; B Kolek; D P Bonner; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.

Authors:  G L Drusano; W Liu; R Perkins; A Madu; C Madu; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  3 in total

1.  Synergistic actions of tailoring enzymes in pradimicin biosynthesis.

Authors:  Kandy Napan; Shuwei Zhang; Whitney Morgan; Thomas Anderson; Jon Y Takemoto; Jixun Zhan
Journal:  Chembiochem       Date:  2014-08-22       Impact factor: 3.164

2.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

3.  Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models.

Authors:  Víctor M Castillo-Acosta; Luis M Ruiz-Pérez; Juan Etxebarria; Niels C Reichardt; Miguel Navarro; Yasuhiro Igarashi; Sandra Liekens; Jan Balzarini; Dolores González-Pacanowska
Journal:  PLoS Pathog       Date:  2016-09-23       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.